Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Cebranopadol, an investigational dual-receptor analgesic, significantly reduced post-surgical pain in two phase 3 trials — and showed lower abuse potential than oxycodone, hydromorphone, and tramadol. The drug targets both NOP and MOP receptors, designed to deliver strong pain relief with fewer addiction-related signals. If confirmed in regulatory review, it could offer clinicians a meaningful new option for managing moderate-to-severe acute pain.
A new painkiller with a lower abuse risk? Phase 3 data on cebranopadol look promising
Adneuris Therapeutics presented phase 3 results for cebranopadol — an investigational analgesic targeting both nociceptin/orphanin FQ peptide (NOP) and mu-opioid peptide (MOP) receptors — at PAINWeek 2026. In two surgical pain trials (ALLEVIATE1 and ALLEVIATE2), cebranopadol 400 µg significantly outperformed placebo in reducing pain intensity after abdominoplasty and bunionectomy, respectively. It also outperformed oxycodone in head-to-head comparisons within ALLEVIATE2.
Beyond efficacy, the abuse-potential data stood out. In human testing among recreational opioid users, cebranopadol showed lower abuse-related signals than hydromorphone, oxycodone, and tramadol — even at doses up to 2.5 times the anticipated therapeutic maximum. Euphoria-like side effects were rare, and withdrawal symptoms after abrupt discontinuation were no more common than with placebo.
By the Numbers
Why it matters: With the opioid crisis still a pressing public health concern, a potent analgesic that may carry a lower abuse and dependence burden would be a significant clinical advance. Pending regulatory review, cebranopadol could give clinicians a new tool for acute pain management that doesn't force a trade-off between efficacy and safety.
